The headline number is 15. Fifteen ingredients banned from cosmetic products sold in the EU from 1 May 2026 under Commission Regulation (EU) 2026/78, also known as Omnibus VIII.
For most brands that have followed previous Omnibus rounds and maintain an active Annex watch, this was a normal quarterly update: cross-check the formulations, flag anything that needs action, instruct the CPSR author. For brands without that process, it meant pulling products from distribution and reformulating under deadline pressure.
Here is what Omnibus VIII contains and what it requires.
What changed
Commission Regulation (EU) 2026/78 amends the EU Cosmetics Regulation (EC) 1223/2009. The regulation entered into force in January 2026 and applied across the EU from 1 May 2026 with no adaptation period. Products not compliant by that date must be withdrawn from EU market shelves immediately.
The regulation does three things.
Bans 15 newly classified CMR substances. Under Article 15 of Regulation 1223/2009, any substance classified as carcinogenic, mutagenic, or toxic for reproduction (CMR categories 1A or 1B) is automatically prohibited in cosmetics unless specifically permitted elsewhere in the Annexes. Omnibus VIII adds 15 such substances to the prohibited list, including perboric acid, carbon nanotubes, and acetone oxime, newly classified since the previous review cycle.
Restricts silver. Silver (nano) with particle diameter between 1 nm and 100 nm, and silver (massive) with particle diameter above 1 mm, are both banned outright. Silver in the middle range (100 nm to 1 mm) is restricted to toothpaste and mouthwash at a maximum concentration of 0.05%. Brands using silver as a preservative or a claims ingredient need to verify particle size and usage category before selling.
Restricts hexyl salicylate. Hexyl 2-hydroxybenzoate, commonly present in fragrance compounds, is now restricted by product type:
- Hydroalcoholic fragrances (leave-on): up to 2%
- Other rinse-off products: up to 0.5%
- Other leave-on products: up to 0.3%
- Products for children under 3 years: more stringent limits apply
If your fragrance supplier provides pre-mixed fragrance compounds, they likely adjusted their formulas ahead of May. If they did not, or if your formula uses fragrance concentrations above these thresholds, the fragrance needs rework before you can sell into the EU.
Why CMR restrictions are hard deadlines, not soft ones
CMR classifications are made by the European Chemicals Agency. When ECHA reclassifies a substance, the EU Commission has a mandatory obligation under the Cosmetics Regulation to restrict or ban it in cosmetics. These are not discretionary decisions and there is no sunset period or phased implementation.
The practical implication: once a substance reaches CMR 1A or 1B classification, the timeline to prohibition is essentially fixed. Brands that monitor ECHA classification updates have several months of advance warning. Brands that only check compliance at product launch are exposed to exactly the situation Omnibus VIII created for unprepared teams in May 2026.
What compliance actually requires
Getting to compliant on an affected formula is not just swapping or reducing one ingredient. The full compliance chain is:
Reformulation. Working with your contract manufacturer or formulator to reduce or replace the restricted substance while maintaining formula performance, stability, and sensory feel.
Revised Cosmetic Product Safety Report. Your CPSR author must document the new formulation. A full stability assessment and updated safety evaluation is required. Depending on the ingredient change, challenge testing may need to be repeated.
Updated Product Information File. The PIF in CPNP must reflect the updated formula, the updated safety report, and the updated ingredient list. A materially different formula is a different notification.
Labelling. If the ingredient removal or restriction changes the INCI list or requires new warning statements, labels must be updated. Print-run lead times mean this needs to be planned ahead of the formula update, not after.
CPNP amendment. If the reformulated product is materially different from the notified version, the CPNP notification must be updated before the product enters the EU market.
The one brands miss
Hexyl salicylate is embedded in thousands of fragrance compounds worldwide. The 2% limit in leave-on fragrance products is high enough that many existing formulas will already be within range. The 0.3% limit in other leave-on products is where problems appear: body moisturisers, leave-in conditioners, and face creams where the fragrance compound was not originally selected with salicylate load in mind.
If you buy fragrance compounds rather than build from raw materials, ask your fragrance supplier for a hexyl salicylate content declaration by product application type. Most suppliers have this now. If they do not, that is itself a signal about supplier quality.
How to build a monitoring system
The Omnibus rounds update roughly every three months. Each round adds or modifies Annex entries. The practice that prevents compliance surprises is a calendar-triggered Annex review, not a launch-triggered one.
Minimum viable monitoring:
- Subscribe to the European Commission's cosmetics regulation updates or the HPRA briefings. The Irish Health Products Regulatory Authority publishes clear plain-English Annex update summaries after each Commission Regulation is adopted.
- Set a quarterly review with your CPSR author to cross-check active formulas against any Annex changes from the preceding quarter.
- Hold a 30-day formulation freeze before any new Annex takes effect, so reformulations triggered by updates have time to be assessed before the deadline.
The brands that were not surprised by Omnibus VIII had this process. The brands that scrambled to pull products in May did not.